Celgene Corp has agreed to pay US$280 million to settle a whistle-blower lawsuit alleging that the pharmaceutical company committed fraud promoting a drug with a notorious history that was repurposed to treat leprosy and another therapy for unapproved cancer treatments, federal prosecutors said on Tuesday.
The agreement settled a lawsuit in Los Angeles federal court by a former Celgene saleswoman who said the New Jersey-based company submitted false claims to Medicare and healthcare programs in 28 US states and Washington, which were all parties to the settlement.
“Patients deserve to know their doctors are prescribing drugs that are likely to provide effective treatment, rather than drugs marketed aggressively by pharmaceutical companies,” Acting US Attorney Sandra Brown said.
The lawsuit filed by Beverly Brown was brought on behalf of the US government under a federal whistle-blower law.
She could receive as much as US$84 million as her share of the settlement.
Celgene denied wrongdoing and settled to avoid uncertainty, distraction and expensive litigation, the company said in a statement.
Brown was an “immunology specialist” trained by Celgene to promote Thalomid and Revlimid drugs for cancer treatments that had not been approved by the US Food and Drug Administration (FDA), the lawsuit said.
Thalomid, another name for thalidomide, a drug prescribed for morning sickness in the 1950s and 1960s that caused severe birth defects, was approved by the agency in 1998 for treating leprosy.
Because Thalomid would only be useful to a fraction of the few hundred leprosy cases diagnosed in the US each year, the company developed a plan to promote the drug for cancer, the lawsuit said.
Doctors can prescribe drugs for other purposes if they think they will be effective, and the company marketed the drug directly to them to treat blood cancers and tumors, the lawsuit said.
The FDA contacted Celgene and sent letters warning about its promotional efforts and for failing to warn about potential fatal risks from the toxic drugs, the lawsuit said.
“Their use in off-label indications was tantamount to human experimentation,” Brown’s lawyers wrote in one court filing. “Celgene compounded this by instructing its sales representatives to conceal the drugs’ risks, including most notably the potential for lethal blood clots.”
While Thalomid and Revlimid, a successor derived from thalidomide, were later approved for limited cancer treatments, their widespread promotion in advance of approvals led Celgene “from the verge of extinction to the multibillion company it is today,” the lawsuit said.
In one of its annual reports, the company said in 1999 that 90 percent of Thalomid prescriptions were for cancer and the drug earned more than US$100 million a year in sales through 2005, when it earned approximately US$389 million, the lawsuit said.
Revlimid brought in more than US$1.7 billion in 2008 and 2009, the lawsuit said.
The lawsuit also claimed that Celgene used false and misleading statements, and paid kickbacks to doctors to prescribe the drugs.
A judge threw out the kickbacks allegation last year, but allowed the lawsuit to proceed.
Under the US False Claims Act, Brown can receive 25 percent to 30 percent of the settlement. She would have been eligible for a smaller share if the government had intervened to take over the case.
In 2012, a former banker earned US$104 million — the largest individual government whistle-blower award — for helping to expose a widespread tax evasion scheme by the Swiss banking behemoth UBS AG.
For Brown, who brought the case in 2010 after leaving the company, it was a long and, at times, emotional experience, attorney Thomas Bienert said.
“I’m extremely pleased to have been a part of recouping this amount of money for the taxpayer and for seeing our courageous client, Beverly Brown, vindicated in pursuing this matter,” Bienert said.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
MAJOR BENEFICIARY: The company benefits from TSMC’s advanced packaging scarcity, given robust demand for Nvidia AI chips, analysts said ASE Technology Holding Co (ASE, 日月光投控), the world’s biggest chip packaging and testing service provider, yesterday said it is raising its equipment capital expenditure budget by 10 percent this year to expand leading-edge and advanced packing and testing capacity amid strong artificial intelligence (AI) and high-performance computing chip demand. This is on top of the 40 to 50 percent annual increase in its capital spending budget to more than the US$1.7 billion to announced in February. About half of the equipment capital expenditure would be spent on leading-edge and advanced packaging and testing technology, the company said. ASE is considered by analysts